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Abstract 
Background 
The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National 
Vaccination Programme (NVP) in September 2010. The impact of PCV10 vaccination against 
invasive pneumococcal disease (IPD) in vaccine-eligible children has been high, possibly due to 
cross-protection against PCV10-related serotypes (serotypes in the same serogroups as the PCV10 
types) in addition to protection against PCV10 serotypes. We evaluated the long-term impact of 
PCV10 vaccination against IPD in vaccine-eligible and older, unvaccinated children six years after 
PCV10 introduction with a special focus on cross-protection. 
Methods 
We used data on IPD from the national, population-based surveillance. A target cohort of vaccine-
eligible children (born June 2010 or later) was followed from 3 months of age until the end of 2016. 
To assess the indirect effect, another cohort of older, PCV10-ineligible children was followed from 
2012 through 2016. IPD rates were compared with those of season- and age-matched reference 
cohorts before NVP introduction.  
Results 
Among vaccine-eligible children, the incidence of all IPD decreased by 79% (95%CI 74 to 83%). 
There was a statistically significant reduction in the incidence of 6A IPD, but for 19A, the reduction 
was non-significant and the incidence of 19A increased towards the end of the study period in the 
older vaccine-eligible children. The increase in non-PCV10 related serotypes was non-significant.  
In the unvaccinated older children, the incidence of all IPD decreased by 33% (95%CI 8 to 52%) 
compared to the reference cohort. There was no impact on serotype 6A or 19A IPD in the 
unvaccinated cohort. 
Conclusion 
Overall, the impact of PCV10 vaccination on IPD was very high in vaccine-eligible children, with a 
major reduction in vaccine-type disease, and without notable replacement by other serotype groups. 
Our data suggest that PCV10 results in long-lasting direct cross-protection against 6A IPD. For 
19A, no net reduction was observed six years after NVP introduction in the vaccine-eligible cohort. 
The indirect impact on IPD in unvaccinated children sustained. 
1 
Introduction 1 
It has been estimated that Streptococcus pneumoniae (the pneumococcus) caused about 14.5 million 2 
episodes of serious pneumococcal disease, including pneumonia, meningitis and febrile 3 
bacteraemia, worldwide in 2000.
1
 The introduction of pneumococcal conjugate vaccines (PCVs) 4 
since 2000 has afforded excellent direct protection for vaccinated children against invasive 5 
pneumococcal disease (IPD) caused by serotypes included in the vaccines. At the same time, the 6 
impact has extended to unvaccinated populations through indirect protection due to reduced 7 
vaccine-type carriage in vaccinated children and the subsequently reduced transmission. However, 8 
replacement in carriage and subsequent disease by serotypes not included in the vaccines has partly 9 
eroded the direct and indirect benefits of vaccination across all age groups and is a growing 10 
concern.
2-811 
In addition to protection against the vaccine serotypes, PCVs have been documented to provide 12 
cross-protection against some vaccine-related serotypes, i.e. serotypes that belong to the same 13 
serogroups as the vaccine serotypes. Previous studies have shown that the seven-valent vaccine 14 
(PCV7, Prevenar, Pfizer), which included serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, reduced also 15 
IPD caused by 6A IPD, but not by 19A or 6C.
3,9,10
 Serotype 19A IPD was among the most common16 
causes of replacement disease after PCV7 introduction.
3,4,11,12
 In 2010, PCV13 (Prevenar 13, Pfizer)17 
with six additional serotypes (1, 3, 5, 6A, 7F, and 19A) replaced PCV7. Recently, cross-protection 18 
against 6C from the 6A component of PCV13 has been reported
13
 .19 
The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix, GSK Vaccines) including 20 
serotypes in the PCV7 + 1, 5 and 7F was introduced into the Finnish National Vaccination 21 
Programme (NVP) after a public tender in September 2010. In addition to providing protection 22 
against vaccine serotypes, PCV10 also had reduced incidence of 6A and 19A IPD among vaccine-23 
eligible children in Finland three years after vaccine introduction into NVP.
6
 Here we report24 
2 
updated data about the overall and indirect long-term impact of PCV10 vaccination against IPD 25 
among vaccine-eligible and unvaccinated older children, with a special focus on cross-protection 26 
against the vaccine-related serotypes. 27 
Methods 28 
The vaccination programme 29 
PCV10 was introduced into the NVP in September 2010. Children born on or after June 1, 2010, 30 
are eligible for vaccination with a 2+1 schedule (primary series at 3 and 5 months and a booster 31 
dose at 12 months of age). There was no catch-up vaccination at PCV10 introduction. In the birth 32 
cohort of 2012, the uptake of at least one dose of PCV10 was estimated at 94% based on data in the 33 
National Vaccination Register.
1434 
In 2009-2011, the effectiveness of PCV10 against vaccine-type IPD was investigated in a nation-35 
wide FinIP vaccine trial, in which over 30,000 children born 2008 through May 2010 were 36 
vaccinated with PCV10.
15
 During the FinIP trial, the PCV10 vaccine coverage varied regionally 37 
from 0 to 60%. Prior to the FinIP trial and the introduction of PCV10 into the NVP, no 38 
pneumococcal conjugate or polysaccharide vaccines were routinely used for healthy children and 39 
adults, and the vaccine uptake was estimated to be less than 2%. 40 
Influenza vaccine was introduced into the NVP in the beginning of the influenza season 2007/2008 41 
for children aged 6 to 36 months. The uptake of this age group has been estimated to vary between 42 
15 and 40%.
1443 
Data sources and case definition 44 
IPD cases were identified from the National Infectious Diseases Register (NIDR), a population-45 
based electronic laboratory surveillance system maintained by the National Institute for Health and 46 
3 
Welfare (THL). It is mandatory for all clinical microbiology laboratories to notify all isolations of 47 
Streptococcus pneumoniae from blood or cerebrospinal fluid to NIDR and the process has been 48 
automated to send electronic reports to the database. Furthermore, the corresponding case isolates 49 
are sent to the national reference laboratory at THL for confirming the species and serotyping. 50 
Currently, more than 97% of the case isolates are received.
16
 IPD case was defined as isolation of S. 51 
pneumoniae from blood or cerebrospinal fluid. The IPD surveillance in Finland and the THL 52 
laboratory methods have been described earlier.
6,17
53 
Vaccination status of each IPD case was verified from the National Vaccination Register and local 54 
electronic vaccination cards. Data on comorbidities were obtained from the national hospital 55 
discharge register (the Care Register for Health Care at THL). The study population was determined 56 
by using data from the Finnish Population Information System. All register-based information was 57 
linked by using the unique national personal identity code which is assigned to all permanent 58 
residents in Finland. 59 
IPD cases were categorized according to the causative serotype into three mutually exclusive 60 
groups: PCV10 serotypes, PCV10-related serotypes (i.e. serotypes belonging to the same 61 
serogroups as vaccine types; in the data: 6A, 6C, 7C, 9N, 18B, 19A, 23A, 23B), or non-PCV10 62 
serotypes. The impact of PCV10 vaccination on each of the three serotype groups was evaluated. In 63 
addition, the impact was assessed separately for serotypes 6A and 19A. 64 
Overall impact of PCV10 vaccination in vaccine-eligible children 65 
To estimate the overall impact of PCV10 vaccination on IPD, the relative reduction in the incidence 66 
of IPD for each serotype group was estimated by comparing a target cohort, comprising all vaccine-67 
eligible children irrespective of vaccination status and born between June 2010 and September 68 
2016, to a season- and age-matched reference cohort in years 2002-2008 (Figure 1, panel A). The 69 
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children who were enrolled in the FinIP trial in years 2009-2010 were excluded from the analysis. 70 
The follow-up period started at 3 months of age (the first scheduled vaccination dose) and lasted 71 
until the end of December 2016 for the target cohort and December 2008 for the reference cohort. 72 
The follow-up thus included children from 3 to 78 months of age.  73 
To assess time trends in the age-specific risk of 19A IPD, age-specific cumulative hazards were 74 
calculated for the target and reference cohorts.  75 
Indirect impact of PCV10 vaccination in unvaccinated children 76 
To estimate the indirect impact of PCV10 vaccination against IPD, the relative reduction in the 77 
incidence of IPD for each serotype group was estimated by comparison of unvaccinated cohorts of 78 
older children after and before PCV10 introduction (Figure 1, panel B). The unvaccinated target 79 
cohort was chosen to comprise children born between January 2006 and May 2010. Children 80 
vaccinated in the FinIP trial with PCV10 were excluded.  The age- and season-matched reference 81 
cohort comprised all children born between January 2000 and May 2004. The follow-up period 82 
started in January 2012 (2006) and lasted until the end of December 2016 (2010) for the target 83 
(reference) cohort. The follow-up included children from 19 to 131 months of age.  84 
Statistical methods 85 
Comparison of IPD incidence rates was performed by using Poisson regression. Vaccine impact 86 
was defined as (1-incidence rate ratio)*100%, comparing the target and reference cohorts. Absolute 87 
rate reductions and the corresponding confidence intervals were calculated from the parameter 88 
estimates with the delta method. No adjustments were made for comorbidities or influenza 89 
vaccinations in the NVP because of the small number of cases, evenly distributed comorbidities in 90 
the study cohorts and the low coverage of the influenza vaccinations. Statistical significance was 91 
deemed at the 5% level. Statistical software R version 3.4.2
18
 was used for all analyses.  92 
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Ethical considerations 93 
As part of its statutory tasks, the National Institute for Health and Welfare (THL) is obliged to 94 
monitor the effectiveness and safety of the vaccines used in NVP. The study plan was approved by 95 
the THL institutional review board (May 23, 2013). Permissions to use the register data for research 96 
were obtained from the relevant register controllers at THL (THL/1090/6.02.00/2013). 97 
 98 
Results 99 
Overall impact of PCV10 vaccination in vaccine-eligible children 100 
Table 1 presents the estimated overall impact of PCV10 vaccination by the serotype groups, based 101 
on comparisons of the entire vaccine-eligible cohort (years 2010-2016) with its reference cohort 102 
(years 2002-2008). Among children targeted for vaccination, the incidence of all IPD decreased by 103 
79% (95% CI 74 to 83%) from 42.9 to 9.2 cases per 100,000 person-years. The incidence of PCV10 104 
serotype IPD decreased by 94% (95% CI 91 to 96%) from 32.3 to 1.9 cases per 100,000 person-105 
years. There was a borderline non-significant increase in non-PCV10 serotypes (IRR 1.53, 95% CI 106 
0.96 to 2.49). Figure 2 shows the evolution of the IPD incidence in children of vaccine-eligible age 107 
by epidemiological year (from July to June).   108 
The incidence of IPD caused by PCV10-related serotypes decreased from 6.3 to 3.8 per 100,000 109 
person-years. This was mainly due to a decrease in the incidence of 6A with a relative reduction of 110 
95% (95% CI 75 to 100%). There was a statistically non-significant reduction of 26% (95% CI -13 111 
to 51%) in 19A.  112 
Apart from the notably high incidence in the epidemiological years 2003/2004-2004/2005, the 113 
incidence of 19A fluctuated over the years with some increase towards the end of the follow-up 114 
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(Figure 3). The annual numbers of cases in 0-1 and 2-5 year-olds varied, respectively, between 0-17 115 
and 0-12. Cases of 19A IPD appeared to occur more often among older children aged 24-78 months 116 
in the target cohort compared to the reference cohort (Figure 4, Supplement Figure 1). The presence 117 
of underlying comorbidities in 19A cases was low and similar in both cohorts. The serotype-118 
specific changes in incidences are presented in Supplement Table 1. 119 
There were six breakthrough cases defined as vaccine-type IPD more than two weeks after 120 
administration of the booster dose at 12 months among the fully vaccinated children (received all 3 121 
doses). The causative serotypes were 19F (2 cases), 23F (2 cases), 6B and 14. No vaccine-type IPD 122 
cases occurred between two primary doses and a booster dose.  123 
Indirect impact of PCV10 vaccination in unvaccinated children 124 
Table 2 presents the relative and absolute rate reductions in IPD incidence, based on the 125 
unvaccinated target cohort of older children (19-131 months of age) during 2012-2016 and its 126 
reference cohort in the years 2006-2010. The incidence of PCV10 serotype IPD  decreased by 58% 127 
(95% CI 37 to 73%) from 5.9 cases in the reference cohort to 2.5 cases per 100,000 person-years in 128 
the target cohort, and the incidence of all IPD by 33% (95% CI 8 to 52%) from 7.3 to 4.8 per 129 
100,000 person-years (Figure 2).  There was no indirect effect against the PCV10-related serotypes. 130 
The incidence of 19A IPD was 0.69 and 0.74 cases per 100,000 person-years, and that of 6A IPD 131 
0.00 and 0.25 cases per 100,000 person-years in the reference and target cohorts, respectively 132 
(Figure 3, Supplement Table 2). The incidence of non-PCV10 serotypes was five times higher in 133 
the target-cohort compared to the reference cohort, but the confidence intervals were wide and the 134 
incidence remained low.  135 
Discussion 136 
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In Finland, the introduction of PCV10 into the NVP has resulted in very high overall impact against 137 
IPD (79%) in the vaccine-eligible birth cohorts six years after PCV10 implementation. This is 138 
explained by the almost complete elimination of PCV10-type and 6A IPD and the low incidence of 139 
other PCV10-related and non-PCV10 serotypes.  140 
In unvaccinated older children, the indirect PCV10 impact on IPD was less notable (33%) due to 141 
the smaller reduction in PCV10-serotype disease and small increases in PCV10-related and non-142 
PCV10 disease. 143 
According to a random-effect meta-analysis
19
, the pooled impact of PCV7 against all IPD was 144 
estimated to vary between 51 and 67% four to seven years after introduction among children <5 145 
years of age. The impact of the combined PCV7 and PCV13 programmes against all IPD among 146 
children <2 years of age have been reported to vary between 64% (Stockholm, Sweden) to 89% 147 
(Norway)
7,20
 and the combined PCV7 and PCV10 programmes among children <5 years of age 148 
from 64% (Quebec) to 80% (the Netherlands) 
5,21
. Thus, our estimate of 79% is consistent with 149 
other settings.    150 
Our data suggest that PCV10 results in long-lasting direct cross-protection against 6A IPD. In 151 
previous studies, the incidence of serotype 6A carriage and invasive disease were largely reduced in 152 
vaccinated children after PCV7 implementation, suggesting direct cross-protection from 6B
3,9,22
, 153 
although not all studies have supported this.
23
 After PCV10 introductions, a non-significant direct 154 
cross-protection against 6A was found in Brazil
24
 and Sweden
13
, and significant protection in 155 
Finland
6
 -- a finding that is further supported by the present study. 156 
After PCV7 introduction in the USA, indirect cross-protection against 6A was observed among 157 
older children and adults
9
 although the effect was smaller and appeared later than the indirect 158 
impact against the PCV7 serotypes.
11
 In Sweden, a significant indirect cross-protection was 159 
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reported after PCV10 vaccination in all unvaccinated age-groups.
13
 In our study, the number of 160 
cases of the older unvaccinated children was too small to assess indirect protection against 6A. 161 
However, 6A is not a replacing serotype among older children and adults in Finland in IPD
25
 or in 162 
carriage in children
26
 suggesting some degree of indirect impact. 163 
In contrast to 6A and our earlier observation based on a three-year follow-up post introduction
6
, we 164 
observed no significant effect of PCV10 against 19A IPD. There were, however, differences by age 165 
and calendar time in 19A disease between the cohorts, as the cases of the vaccine-eligible cohort 166 
tended to be older and occur more often towards the end of the follow-up than those of the reference 167 
cohort. One explanation could be the increasing infection pressure from 19A, also seen in adult age 168 
groups 2012-2013 onwards
25
; another  speculation is that the 19F component in PCV10 induces 169 
initial cross-protection which wanes with age thus rendering vaccinated children susceptible again 170 
to 19A in lack of specific 19A immunity. The small number of cases and year-to-year variability 171 
make firm conclusions difficult.  172 
After PCV7 introduction in the USA and several countries in Europe, 19A carriage and the 173 
incidence of 19A IPD increased rapidly among children targeted to vaccination and also in older 174 
age groups.
3,4,7,11,22
 Our results are in contrast with the 3- to 4-fold increases of 19A IPD post-PCV7 175 
in the USA in children
11
 , although the increases in adults have been similar.
11,25
 In the US, the 176 
increase in 19A disease was mainly due to the increase in antimicrobial-resistant clonal complex 177 
(CC) 320 and a concurrent decrease in antimicrobial-susceptible CC199, suggesting that antibiotic 178 
selection pressure could have contributed to the 19A emergence
27,28
. In Finland, the outpatient 179 
antimicrobial use is lower than in USA
29
, and also lower than the average for all European Union 180 
countries
30
, although higher compared to the Nordic neighbors. The introduction of PCV10 into the 181 
vaccination program has resulted in further reduction of antimicrobial use in children.
31
 The 182 
antimicrobial non-susceptibility of pneumococci has also decreased in all age-groups and especially 183 
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among young children during the PCV10 program.
32,33
 For 19A, antimicrobial susceptible clones 184 
(especially ST994 and ST199) have become dominant both in children
34
 and among elderly 185 
people
35
 during the post-PCV10 period in Finland resulting in low proportion of antimicrobial 186 
resistance. 187 
In our first evaluation three years after PCV10 implementation in Finland, the 19A IPD incidence 188 
had declined significantly by 62% in the vaccine-eligible cohort (children aged 3-42 months).
6
 189 
Statistically significant direct effectiveness against 19A IPD was reported with matched case-190 
control studies in Brazil (82%, children aged 2.6-53.1 months) and Quebec (79%, children aged 2-191 
59 months) after at least one PCV10 dose.
24,36
 In the Netherlands, where PCV10 was introduced 192 
about 5 years after PCV7 with a 3+1 schedule, the incidence of 19A IPD was lower in the PCV10-193 
eligible cohort than in the PCV7-eligible cohort.  However, the cross-protective effect of 19A was 194 
inconclusive, as the incidence of both PCV10-related and non-related serotypes was low.
5
 In 195 
Sweden, where PCV7 was first introduced in the years 2007 through 2009 depending on the county 196 
and then replaced by PCV10 or PCV13 in 2009-2010, no direct cross-protection against 19A was 197 
reported in the PCV10 areas.
13
  198 
The strengths of the current study setting include high data completeness (≈80% of isolates in years 199 
2002-2008 were available for serotyping, and ≈100% after that) and a well-established and 200 
consistent reporting in a population-based nationwide surveillance system. The personal identity 201 
code allowed linkage between different registers to find vaccination histories and health statuses for 202 
the IPD cases.   203 
An apparent limitation of our study design, based on a before-after comparison, is its inclination to 204 
bias due to secular trends. In addition, the small numbers of cases caution against over-205 
interpretation of analyses on individual serotypes. The age- and calendar-time related changes 206 
observed in 19A IPD may equally well be explained by chance alone: the annual numbers of 19A 207 
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cases in under 2-year-olds in 2002-2016 ranged between 0 and 17, with median of 5. Therefore, 208 
firm conclusions can only be made on the overall IPD level, where randomness and serotype-209 
specific secular trends are balanced out with sufficient numbers and follow-up time. In addition, the 210 
vaccine-induced dynamics between serotypes in the post-vaccination period may limit comparisons 211 
with the reference cohort. Depending on the levels of competition between serotypes and vaccine 212 
coverage, replacement and herd protection in carriage and disease may occur differently.
37
 213 
Moreover, influenza vaccinations that started in fall 2007 for children 6 to 36 months of age, may 214 
have prevented some IPD cases. However, the vaccination coverage was 40% in 2007 to 2009 but 215 
less than 20% during the PCV10 program
14
, which might result in a conservative estimate of the 216 
PCV10 impact.    217 
In conclusion, PCV10 vaccination has resulted in a very high impact against PCV10 serotypes, no 218 
notable replacement due to non-PCV10 serotypes, and long-lasting direct cross-protection against 219 
6A IPD among vaccine-eligible children. Most importantly, the net impact on IPD irrespective of 220 
serotypes six years after PCV implementation in Finland is among the largest reported 221 
globally.
5,7,8,19
    222 
 223 
 224 
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Table 1. Incidence rates of invasive pneumococcal disease (IPD) and the corresponding relative and 
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Table 2. Incidence rates of invasive pneumococcal disease (IPD) and the corresponding relative and 
absolute incidence rate reductions, based on the comparison of an unvaccinated target cohort (2012-
2016) vs. a reference cohort (2006-2010). 
 
Table 1.  
  Incidence per 100,000 person-years (N) Target cohort vs. reference cohort 
  
Reference cohort 
2002-2008* 
Target cohort 
2010-2016** 
Relative rate reduction, % 
(95% CI) 
Absolute rate reduction per 
100,000 person-years (95% CI) 
  
Follow-up yrs 
1211504 
Follow-up yrs 
1243145 
    
Any culture confirmed IPD 42.9 (520) 9.2 (114) 78.6 (73.9, 82.6) 33.8 (29.7, 37.8) 
PCV10 serotypes 32.3 (391) 1.9 (23) 94.3 (91.5, 96.3) 30.4 (27.1, 33.7) 
PCV10-related serotypes 6.3 (76) 3.8 (47) 39.7 (13.7, 58.4) 2.5 (0.72, 4.3) 
Non-PCV10 serotypes 2.3 (28) 3.5 (44)  -53.1 (-148.6, 4.1)  -1.2 (-2.6, 0.12) 
Not known 2.1 (25) 0 (0) NA NA 
*Age 3-78 months, born Jun 2002 – Sep 2008 
**Age 3-78 months, born Jun 2010 – Sep 2016 
NA = not applicable 
 
 
Table 2. 
Serotype group Incidence per 100,000 person-years (N) Unvaccinated target cohort vs. reference cohort 
  
Reference cohort 
2006-2010* 
Target cohort 
2012-2016** 
Relative rate reduction, % 
(95% CI) 
Absolute rate reduction per 
100,000 person-years (95% CI) 
  
Follow-up yrs 
1309618 
Follow-up yrs 
1221933     
Any culture confirmed IPD 7.3 (95) 4.8 (59) 33.4 (8.2, 52.1) 2.4 (0.52, 4.3) 
PCV10-serotypes 5.9 (77) 2.5 (30) 58.2 (37.1, 73.0) 3.4 (1.8, 5) 
PCV10-related serotypes 0.69 (9) 1.2 (15)  -78.6 (-325.3, 20.5)  -0.54 (-1.3, 0.23) 
Non-PCV10 serotypes 0.23 (3) 1.2 (14)  -400.2 (-2069.8, -63.3)  -0.92 (-1.8, -0.26) 
Not known 0.46 (6) 0 (0) NA NA 
*Age 19-131 months, born Jan 2000 – May 2004 
**Age 19-131 months, born Jan 2006 – May 2010 
NA = not applicable 
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Supplementary Appendix 
Supplement to: Rinta-Kokko H, Palmu AA, Auranen K, et al. Long-term impact of 10-valent pneumococcal 
conjugate vaccination on invasive pneumococcal disease among children in Finland 
 
Supplement Table 1. Incidence rates of invasive pneumococcal disease (IPD) of individual PCV10 serotypes 
and the corresponding relative and absolute incidence rate reductions, based on the comparison of the 
PCV10-eligible target cohort (2010-2016) vs. a reference cohort (2002-2008).  
Serotype Incidence per 100,000 person-years (N) Target cohort vs. reference cohort 
  
Reference cohort 
2002-2008* 
Target cohort 
2010-2016** 
Relative rate reduction, % 
(95% CI) 
Absolute rate reduction per 
100,000 person-years (95% CI) 
  
Follow-up yrs 
1211504 
Follow-up yrs 
1243145 
    
1 0.08 (1) 0.08 (1) 2.6 (-2364.5, 96.2) 0 (-0.2, 0.2) 
4 0.91 (11) 0 (0) 100 (80.8, 100) 0.9 (0.4, 1.4) 
5 0 (0) 0 (0) NA 0 (0, 0) 
6B 10.9 (132) 0.24 (3) 97.8 (94.2, 99.5) 10.7 (8.8, 12.5) 
7F 0.66 (8) 0.08 (1) 87.8 (33.6, 99.3) 0.6 (0.1, 1.1) 
9V 1.24 (15) 0 (0) 100 (86.3, 100) 1.2 (0.6, 1.9) 
14 8.58 (104) 0.64 (8) 92.5 (85.6, 96.6) 7.9 (6.2, 9.7) 
18C 2.31 (28) 0.08 (1) 96.5 (83.7, 99.8) 2.2 (1.4, 3.1) 
19F 3.71 (45) 0.4 (5) 89.2 (75.2, 96.3) 3.3 (2.2, 4.5) 
23F 3.88 (47) 0.32 (4) 91.7 (79.6, 97.5) 3.6 (2.4, 4.7) 
6A 1.57 (19) 0.08 (1) 94.9 (75.3, 99.7) 1.5 (0.8, 2.2) 
19A 4.21 (51) 3.14 (39) 25.5 (-12.8, 51.2) 1.1 (-0.5, 2.6) 
*Age 3-78 months, born Jun 2002 – Sep 2008 
**Age 3-78 months, born Jun 2010 – Sep 2016 
NA = not applicable 
 
Supplement Table 2. Incidence rates of invasive pneumococcal disease (IPD) of individual PCV10 serotypes 
and the corresponding relative and absolute incidence rate reductions, based on the comparison of an 
unvaccinated target cohort (2012-2016) vs. a reference cohort (2006-2010). 
Serotype Incidence per 100,000 person-years (N) Unvaccinated target cohort vs. reference cohort 
  
Reference cohort 
2006-2010* 
Target cohort 
2012-2016** 
Relative rate reduction, % 
(95% CI) 
Absolute rate reduction per 
100,000 person-years (95% CI) 
  
Follow-up yrs 
1309618 
Follow-up yrs 
1221933 
 
  
1 0 (0) 0 (0) NA 0 (0, 0) 
4 0.15 (2) 0 (0) 100 (-66.5, 100) 0.2 (-0.06, 0.4) 
5 0 (0) 0 (0) NA 0 (0, 0) 
6B 0.76 (10) 0.41 (5) 46.4 (-50.8, 83.3) 0.4 (-0.2, 1.0) 
7F 0.38 (5) 0.25 (3) 35.7 (-162.1, 86.8) 0.1 (-0.3, 0.6) 
9V 0 (0) 0.16 (2)  -Inf (-Inf, 40)  -0.2 (-0.4, 0.06) 
14 1.68 (22) 0.33 (4) 80.5 (49.1, 94.3) 1.4 (0.6, 2.1) 
18C 1.3 (17) 0.49 (6) 62.2 (9, 86.4) 0.8 (0.08, 1.5) 
19F 0.46 (6) 0.16 (2) 64.3 (-55.1, 94.8) 0.3 (-0.1, 0.7) 
23F 1.15 (15) 0.65 (8) 42.8 (-31.6, 77) 0.5 (-0.3, 1.2) 
6A 0 (0) 0.25 (3)  -Inf (-Inf, -7.3)  -0.3 (-0.5, 0.03) 
19A 0.69 (9) 0.74 (9)  -7.2 (-174.5, 58.2)  -0.05 (-0.7, 0.6) 
*Age 19-131 months, born Jan 2000 – May 2004 
**Age 19-131 months, born Jan 2006 – May 2010 
NA = not applicable 
 
 2 
 
 
Supplement Figure 1. Age-specific cumulative hazards of 19A IPD in the PCV10-eligible target cohort and 
the reference cohort.  
 
